Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc. (NASDAQ: AGEN) generates a steady stream of news centered on its immuno-oncology pipeline, with particular focus on the botensilimab (BOT) and balstilimab (BAL) combination. As a Lexington, Massachusetts-based biological products manufacturer focused on cancer immunotherapy, the company’s updates frequently highlight progress in clinical trials, early-access frameworks and strategic collaborations.
Many recent headlines relate to BOT+BAL’s performance in advanced solid tumors. Agenus reports data from the C-800-01 Phase 1b trial, which evaluates the combination across multiple refractory cancers, and from the global BATTMAN CO.33 Phase 3 trial in microsatellite-stable colorectal cancer conducted with the Canadian Cancer Trials Group and international academic partners. News coverage also includes peer-reviewed publications, such as results in treatment-refractory ovarian cancer, and presentations at major oncology congresses.
Another major theme in Agenus news is patient access. The company has announced that France’s medicines agency authorized a national Autorisation d’Accès Compassionnel (AAC) protocol for BOT+BAL, enabling fully reimbursed hospital-based access for eligible patients with microsatellite-stable metastatic colorectal cancer, certain ovarian cancers and soft-tissue sarcomas. Additional stories describe named-patient and early-access programs in other geographies where regulations allow.
Strategic and corporate developments also feature prominently. Agenus has disclosed a collaboration with Zydus Lifesciences involving the sale of biologics manufacturing facilities in California, an equity investment in Agenus, and an exclusive license for BOT and BAL in India and Sri Lanka, along with the creation of Zylidac Bio LLC to house the acquired U.S. manufacturing assets. Investors following AGEN news can expect updates on clinical milestones, regulatory interactions, early-access expansions, manufacturing partnerships and periodic financial and corporate communications.
Agenus (NASDAQ: AGEN) will present new data on two promising immunotherapy candidates at the SITC 2024 Annual Meeting in Houston. The presentations will feature botensilimab, an Fc-enhanced anti-CTLA-4 antibody showing efficacy in treatment-resistant cancers, and AGEN1721, a first-in-class bifunctional antibody targeting FAP and TGFβ.
Botensilimab enhances both innate and adaptive immunity, demonstrating effectiveness in glioblastoma, melanoma, colorectal, pancreatic, and breast cancers. AGEN1721 works by remodeling the tumor microenvironment, depleting cancer-associated fibroblasts, and neutralizing TGFβ's immunosuppressive effects, transforming cold tumors into immune-responsive environments.
Agenus (NASDAQ: AGEN), a company focused on developing immunological cancer treatments, has scheduled its third quarter 2024 financial results release before market opening on Tuesday, November 12th, 2024. The company will host a conference call and webcast at 8:30 a.m. ET the same day, featuring executive discussions of the results and a corporate update.
GSK announced positive topline data from a phase 3 trial evaluating the co-administration of AREXVY (RSV vaccine) and SHINGRIX (shingles vaccine) in adults 50 years and older. The study met its primary endpoint, showing a non-inferior immune response when the vaccines were given together compared to separate administration. Co-administration was well-tolerated with acceptable safety profiles.
Key findings include:
- Comparable immune responses in co-administration and separate administration groups
- Most common adverse events: injection site pain, fatigue, and myalgia
- Similar duration of adverse events across groups
GSK plans to submit these results to support regulatory submissions to the FDA, EMA, and other regulators. The company aims to reduce barriers to adult immunization by potentially decreasing the number of healthcare visits required for vaccination.
Agenus Inc. (Nasdaq: AGEN) presented promising data at the ESMO Congress for their Phase 1 study of botensilimab (BOT) and balstilimab (BAL) combination in refractory sarcomas. Key findings include:
- 23% overall response rate (ORR) in the full sarcoma cohort
- 21.7 months median duration of response (DOR)
- 69% 12-month overall survival (OS)
- 39% ORR in angiosarcoma subtype
- Manageable and reversible adverse event profile
The study involved 64 patients with relapsed/refractory sarcomas, with a median of 3 prior lines of therapy. The results suggest BOT/BAL could be a significant treatment option for patients with alternatives, particularly in 'cold' sarcomas like visceral angiosarcoma, leiomyosarcoma, and dedifferentiated liposarcoma.
Agenus Inc. (Nasdaq: AGEN) announced that updated data from the clinical trial of botensilimab and balstilimab in refractory sarcomas will be presented at the ESMO Congress 2024 in Barcelona. The presentation will showcase updated efficacy and safety data from the ongoing Phase 1 trial, highlighting the potential of this combination therapy in treating patients with refractory sarcomas, including visceral angiosarcoma and leiomyosarcoma.
Botensilimab, a novel Fc-enhanced CTLA-4 inhibitor, and balstilimab, a PD-1 antibody, have shown promising clinical responses in multiple tumor types, including 'cold' tumors typically unresponsive to standard therapies. The presentation, titled 'Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase 1 study,' will be given by Dr. Breelyn A. Wilky on September 13th, 2024.
Agenus Inc. (Nasdaq: AGEN), a leader in immunological cancer treatments, has announced its participation in three upcoming investor conferences in September. The company's executives, including CEO Dr. Garo Armen, will attend:
1. Wells Fargo Healthcare Conference on September 5th at 12:45 p.m. ET in Boston, MA.
2. HC Wainwright Global Investment Conference on September 10th at 8:30 a.m. ET in New York, NY.
3. Baird Global Healthcare Conference on September 10th at 2:00 p.m. ET in New York, NY.
Live webcasts and replays will be available for the Wells Fargo and HC Wainwright conferences on the company's website and provided links. These events offer investors an opportunity to gain insights into Agenus' latest developments and future plans in cancer immunotherapy.
Agenus (NASDAQ: AGEN) has appointed Tom Harrison to its Board of Directors, aiming to leverage his extensive expertise in healthcare advertising, branding, and strategic advising to elevate the company's visibility.
Harrison, former Chairman Emeritus of DAS at Omnicom, led the world's largest marketing services group, expanding its client base to over 5,000 and generating annual revenues of over $6 billion. He also co-founded the successful healthcare agency Harrison & Star.
Currently, Harrison is a Senior Operating Partner at Merida Capital Partners and serves on the boards of AFC Gamma and Acurx Pharmaceuticals.
Agenus believes Harrison's background will be instrumental in enhancing their communication strategies, educating stakeholders about their innovative immunotherapy pipeline, and elevating their reputation within the scientific and medical communities.
Agenus Inc. (Nasdaq: AGEN) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
1. Robust Phase 2 data for BOT/BAL in metastatic MSS CRC, showing a 19.4% ORR and 90% 6-month OS rate.
2. Promising results in neoadjuvant CRC with 78% of patients achieving ≥50% tumor reduction.
3. Initiation of global regulatory engagements for BOT/BAL approval pathways.
4. Q2 2024 revenue of $23.5 million and a net loss of $54.8 million.
5. Cash balance of $93.7 million as of June 30, 2024.
Agenus is pursuing partnerships and financing options to support its BOT/BAL program and other pipeline assets.
Agenus Inc. (NASDAQ: AGEN) has published a groundbreaking study in Cancer Discovery on botensilimab, their novel Fc-enhanced anti-CTLA-4 antibody. The study highlights botensilimab's effectiveness against treatment-resistant cancers, including those unresponsive to conventional immunotherapy. Key findings include:
1. Demonstrated activity across multiple cancer types
2. Unique Fc-enhanced design enabling multifunctional immune activation
3. Efficacy independent of typical limitations like tumor neoantigen burden
4. Ability to remodel the tumor microenvironment, transforming 'cold' tumors into 'hot' ones
5. Promising results in nine difficult-to-treat cancers, including microsatellite stable colorectal cancer
This research suggests botensilimab's potential to overcome major challenges in cancer treatment, offering hope to patients with options.
Agenus Inc. (Nasdaq: AGEN), a leading developer of novel immunological agents for cancer treatment, has announced its plans to release second quarter 2024 financial results on Thursday, August 8, 2024, before the market opens. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results and provide a corporate update. Interested parties can register for the conference call, which has the Conference ID: 73242. A live webcast and replay of the call will be available on the company's investor relations website.